Q-omics provides the consensus-scored H3P35 profile across patient tissues and cancer cell-line models. H3P35 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, H3P35 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, H3P35 RNA expression shows 9,481 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight STAD, LUSC, and CCRCC as cancer lineages where H3P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3P35 survival associations across molecular data types. H3P35 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3P35 RNA expression–survival associations across cancer types. High H3P35 expression shows unfavorable associations in STAD, KIRP, COAD, BLCA, HNSC and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for H3P35 RNA expression.
This table summarizes H3P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for H3P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3P35 shows higher tumor expression in LUSC. The LUSC box plot shows higher H3P35 RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .042).
This table shows molecular features associated with H3P35 in patient tissues and cancer cell lines. In patient samples, H3P35 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
